Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTD1801 vs UDCA in Adolescents With Primary Sclerosing Cholangitis
NCT03678480Phase 2Withdrawn
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of berberine ursodeoxycholate in Primary Sclerosing Cholangitis (PSC) (2 arms), sponsored by HighTide Therapeutics, Inc. Primary endpoint: Change in gamma-glutamyl transferase (GGT) at 18 weeks. Planned start Mar 2021; status: withdrawn.
02
Drugs
berberine ursodeoxycholate
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03678480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678480.